

Capital Raise Brief

Private Intelligence Infrastructure for Biopharma

The market that cannot verify what is true will pay for the system that can.

\$140B

Outsourced intelligence market

\$67B

TAM: Pharma Analytics

78%

Execs cite AI trust barrier

47%

AI fabrication acceptance

CONFIDENTIAL — Qualified Investors Only

The Product

Private intelligence operating system. Six layers: ingestion, normalization, validation, hallucination containment, role-based delivery, institutional memory. Only hallucination containment system in market.

Revenue

\$229/mo \$250K+/mo per organization. Entry through practitioners, expansion through departments, enterprise through organization-wide deployment.

Why Now

AI adoption in biopharma is inevitable. Trust is the bottleneck. 78% of executives cite hallucination as the primary barrier. First company to earn institutional trust owns the category.

The Moat

Hallucination containment + institutional memory = compounding switching costs. Every correction, decision, and review makes the system more valuable. Leaving means abandoning organizational intelligence.

The first company to build trusted intelligence infrastructure for biopharma does not win a feature market. It wins the decision layer.

Contact

investors@aimwellbio.com | aimwellbio.com | All inquiries confidential.